journal article·2011-06-28Open access

Layer-by-Layer Nanoparticles with a pH-Sheddable Layer forin VivoTargeting of Tumor Hypoxia

Zhiyong Poon, Dongsook Chang, Xiaoyong Zhao, Paula T Hammond

ACS Nano· Volume 5· Issue 6

Abstract

Inspired by the simplicity and versatility of layer-by-layer (LbL) assembly, we applied multilayered polyelectrolyte assemblies on nanoparticles to create viable systemic delivery systems. Focusing on tumor-specific delivery, LbL nanoparticles that exhibit a pH-sensitive outer stealth layer are demonstrated to target and be retained in hypoxic tumor regions. The neutral layers shed in response to acidity to reveal a charged nanoparticle surface that is readily taken up by tumor cells. The first in vivo demonstration of this mechanism of targeting is presented, as well as an initial examination of the mechanism of uptake of the nanoparticles. We further demonstrate that this concept for tumor targeting is potentially valid for a broad range of cancers, with applicability for therapies that target hypoxic tumor tissue.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Polymer Surface Interaction Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Koch Institute for Integrative Cancer Research at MIT, Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

References (53)

Show source-provided references
1. Decher G. · Curr. Opin. Colloid Interface Sci. · 1998 · 3 · 3210.1016/S1359-0294(98)80039-3 ↗
2. Hammond P. T. · Adv. Mater. (Weinheim, Ger.) · 2004 · 16 · 127110.1002/adma.200400760 ↗
3. Lynn D. M. · Adv. Mater. (Weinheim, Ger.) · 2007 · 19 · 411810.1002/adma.200701748 ↗
4. Boudou T. · Adv. Mater. (Weinheim, Ger.) · 2010 · 22 · 44110.1002/adma.200901327 ↗
5. Davis M. E. · Nat. Rev. Drug Discovery · 2008 · 7 · 77110.1038/nrd2614 ↗
6. Duncan R. · Nat. Rev. Drug Discovery · 2003 · 2 · 34710.1038/nrd1088 ↗
7. Haag R. · Angew. Chem., Int. Ed. · 2006 · 45 · 119810.1002/anie.200502113 ↗
8. Immordino M. L. · Int. J. Nanomed. · 2006 · 1 · 29710.2217/17435889.1.3.297 ↗
9. Angelatos A. S. · Soft Matter · 2006 · 2 · 1810.1039/B511930H ↗
10. Schneider G. · Nano Lett. · 2004 · 4 · 183310.1021/nl0490826 ↗
11. Elbakry A. · Nano Lett. · 2009 · 9 · 205910.1021/nl9003865 ↗
12. Schneider G. F. · Nano Lett. · 2009 · 9 · 63610.1021/nl802990w ↗
13. Cortez C. · Adv. Mater. (Weinheim, Ger.) · 2006 · 18 · 199810.1002/adma.200600564 ↗
14. De K. S. · Adv. Funct. Mater. · 2007 · 17 · 375410.1002/adfm.200700416 ↗
15. Sexton A. · ACS Nano · 2009 · 3 · 339110.1021/nn900715g ↗
16. Saurer E. M. · Acta Biomater. · 2009 · 5 · 91310.1016/j.actbio.2008.08.022 ↗
17. Ochs C. J. · Langmuir · 2010 · 27 · 127510.1021/la104232r ↗
18. Chong S.-F. · Langmuir · 2011 · 27 · 172410.1021/la104510e ↗
19. Becker A. L. · Small · 2010 · 6 · 1836
20. Choi C. H. J. · Proc. Natl. Acad. Sci. U. S. A. · 2010 · 107 · S1235/1
21. Bartlett D. W. · Proc. Natl. Acad. Sci. U. S. A. · 2007 · 104 · 1554910.1073/pnas.0707461104 ↗
22. Kukowska-Latallo J. F. · Cancer Res. · 2005 · 65 · 531710.1158/0008-5472.CAN-04-3921 ↗
23. Kamphuis M. M. J. · J. Am. Chem. Soc. · 2010 · 132 · 1588110.1021/ja106405c ↗
24. Cortez C. · ACS Nano · 2007 · 1 · 9310.1021/nn700060m ↗
25. Brown J. M. · Nat. Rev. Cancer · 2004 · 4 · 43710.1038/nrc1367 ↗
26. Henning T. · Anti-Cancer Drugs · 2004 · 15 · 710.1097/00001813-200401000-00002 ↗
27. Harris T. J. · Small · 2008 · 4 · 130710.1002/smll.200701319 ↗
28. Van V. E. · Leukemia · 2005 · 19 · 162810.1038/sj.leu.2403866 ↗
29. Zalipsky S. · Bioconjugate Chem. · 2007 · 18 · 186910.1021/bc7001902 ↗
30. Lee E. S. · J. Controlled Release · 2008 · 129 · 22810.1016/j.jconrel.2008.04.024 ↗
31. Lee E. S. · Nano Lett. · 2005 · 5 · 32510.1021/nl0479987 ↗
32. Wu X. L. · Bioconjugate Chem. · 2010 · 21 · 20810.1021/bc9005283 ↗
33. Koo H. · Chem. Commun. (Cambridge, U. K.) · 2010 · 46 · 566810.1039/c0cc01413c ↗
34. Xu J. · Yaoxue Xuebao · 2009 · 44 · 1328
35. Yang X. · Bioconjugate Chem. · 2010 · 21 · 49610.1021/bc900422j ↗
36. Wu X. L. · Bioconjugate Chem. · 2010 · 21 · 20810.1021/bc9005283 ↗
37. Oishi M. · Bioconjugate Chem. · 2006 · 17 · 67710.1021/bc050364m ↗
38. Gillies E. R. · Bioconjugate Chem. · 2005 · 16 · 36110.1021/bc049851c ↗
39. Sullivan, R. M.The Multifactorial Nature of Hypoxia-Induced Drug Resistance in Cancer: Involvement of Hypoxia-Inducible Factor 1; 2008.
40. Tannock I. F. · Cancer Metastasis Rev. · 2001 · 20 · 12310.1023/A:1013125027697 ↗
41. Michalski B. · Przegl. Menopauzalny · 2009 · 8 · 196
42. Jain R. K. · Nat. Med. (N. Y., NY, U. S.) · 2001 · 7 · 987
43. Inoue H. · Biomacromolecules · 2005 · 6 · 2710.1021/bm0495856 ↗
44. Lesch H. P. · Expert Opin. Drug Delivery · 7 · 55110.1517/17425241003677749 ↗
45. Alexis F. · Mol. Pharmaceutics · 2008 · 5 · 50510.1021/mp800051m ↗
46. Maeda H. · J. Controlled Release · 2000 · 65 · 27110.1016/S0168-3659(99)00248-5 ↗
47. Kjeken R. · Biochem. J. · 2001 · 357 · 49710.1042/bj3570497 ↗
48. Kinsella M. G. · Atherosclerosis (Amsterdam, Netherlands) · 2004 · 175 · 51
49. Hansen M. · Adv. Drug Delivery Rev. · 2008 · 60 · 57210.1016/j.addr.2007.09.003 ↗
50. Moghimi S. M. · Pharmacol. Rev. · 2001 · 53 · 28310.1016/S0031-6997(24)01494-7 ↗
51. Pirollo K. F. · Trends Biotechnol. · 2008 · 26 · 55210.1016/j.tibtech.2008.06.007 ↗
52. Greish K. · Methods Mol. Biol. (Totowa, NJ, U. S.) · 2010 · 624 · 2510.1007/978-1-60761-609-2_3 ↗
53. Gittins D. I. · J. Phys. Chem. B · 2001 · 105 · 684610.1021/jp0111665 ↗